The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B
- DOI
- 10.3389/fphar.2021.720619
- Published
- 2021-08-27
- Container
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2021.720619,
title = {The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B},
author = {Shi-Long Jiang and Zhi-Bin Wang and Tao Zhu and Ting Jiang and Jiang-Feng Fei and Chong Liu and Chao Luo and Yan Cheng and Zhao-Qian Liu},
year = {2021},
journal = {Frontiers in Pharmacology},
doi = {10.3389/fphar.2021.720619},
url = {https://doi.org/10.3389/fphar.2021.720619}
}RIS
TY - JOUR TI - The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B AU - Shi-Long Jiang AU - Zhi-Bin Wang AU - Tao Zhu AU - Ting Jiang AU - Jiang-Feng Fei AU - Chong Liu AU - Chao Luo AU - Yan Cheng AU - Zhao-Qian Liu PY - 2021 JO - Frontiers in Pharmacology DO - 10.3389/fphar.2021.720619 UR - https://doi.org/10.3389/fphar.2021.720619 ER -
APA
Jiang, S., Wang, Z., Zhu, T., Jiang, T., Fei, J., Liu, C., Luo, C., Cheng, Y., & Liu, Z. (2021). The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.720619
Source records
- crossref · retrieved 2026-09-25T09:07:51.272Z